Abstract
Hypoxia-inducible factor-1 (HIF-1), a heterodimeric (containing α and β subunits) transcription factor, is involved in hypoxia response pathway that regulates the expression of many tumorrelated genes. The stabilized HIF-1 heterodimer couples to the general co-activators p300/CBP (CREB binding protein), forming an active transcription factor to initiate hypoxic responses. Inhibiting the transcription factor-coactivator HIF-1α-p300/CBP interaction represents an attractive approach for blocking hypoxia pathway in tumors. Recently, diverse HIF-1α-p300/CBP inhibitors have been designed and their anti-tumor activities have been evaluated. The developments of inhibitors of HIF-1α- p300/CBP are discussed in this review. An outline of structures and biological activities of these inhibitors can be traced, along with the approaches for inhibitors discovery. The challenges in identifying novel and selective potent inhibitors of HIF-1α-p300/CBP are also put forward.
Keywords: Anticancer, cancer therapy, HIF-1α/p300 inhibitors, hypoxia response pathway, hypoxia-inducible factor-1, p300/CREB binding protein.
Mini-Reviews in Medicinal Chemistry
Title:Recent Advances in the Discovery of HIF-1α-p300/CBP Inhibitors as Anti-Cancer Agents
Volume: 18 Issue: 4
Author(s): Jinlian Wei, Yingrui Yang, Mengchen Lu, Yonghua Lei, Lili Xu, Zhengyu Jiang, Xiaoli Xu, Xiaoke Guo, Xiaojin Zhang, Haopeng Sun*Qidong You
Affiliation:
- Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009,China
Keywords: Anticancer, cancer therapy, HIF-1α/p300 inhibitors, hypoxia response pathway, hypoxia-inducible factor-1, p300/CREB binding protein.
Abstract: Hypoxia-inducible factor-1 (HIF-1), a heterodimeric (containing α and β subunits) transcription factor, is involved in hypoxia response pathway that regulates the expression of many tumorrelated genes. The stabilized HIF-1 heterodimer couples to the general co-activators p300/CBP (CREB binding protein), forming an active transcription factor to initiate hypoxic responses. Inhibiting the transcription factor-coactivator HIF-1α-p300/CBP interaction represents an attractive approach for blocking hypoxia pathway in tumors. Recently, diverse HIF-1α-p300/CBP inhibitors have been designed and their anti-tumor activities have been evaluated. The developments of inhibitors of HIF-1α- p300/CBP are discussed in this review. An outline of structures and biological activities of these inhibitors can be traced, along with the approaches for inhibitors discovery. The challenges in identifying novel and selective potent inhibitors of HIF-1α-p300/CBP are also put forward.
Export Options
About this article
Cite this article as:
Wei Jinlian, Yang Yingrui, Lu Mengchen, Lei Yonghua, Xu Lili, Jiang Zhengyu, Xu Xiaoli, Guo Xiaoke, Zhang Xiaojin, Sun Haopeng*, You Qidong, Recent Advances in the Discovery of HIF-1α-p300/CBP Inhibitors as Anti-Cancer Agents, Mini-Reviews in Medicinal Chemistry 2018; 18 (4) . https://dx.doi.org/10.2174/1389557516666160630124938
DOI https://dx.doi.org/10.2174/1389557516666160630124938 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emergence of Lipid-Based Vesicular Carriers as Nanoscale Pharmacotherapy in Rheumatoid Arthritis
Recent Patents on Nanomedicine Models for the Study of Angiogenesis
Current Pharmaceutical Design Small Molecules ATP-Competitive Inhibitors of FLT3: A Chemical Overview
Current Medicinal Chemistry Radial Distribution of Elasticity in Porcine Thoracic Aorta
Vascular Disease Prevention (Discontinued) Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry Specificity of Binding in Protein Kinases
Current Enzyme Inhibition The “Parkinsonian Heart”: From Novel Vistas to Advanced Therapeutic Approaches in Parkinsons Disease
Current Medicinal Chemistry Coumarinyl Aryl/Alkyl Sulfonates with Dual Potential: Alkaline Phosphatase and ROS Inhibitory Activities: In-Silico Molecular Modeling and ADME Evaluation
Letters in Drug Design & Discovery Antiproliferative Effects of Nerium oleander Leaves and Their Cardiac Glycosides Odoroside A and Oleandrin on MCF-7 Cancer Cells
Current Traditional Medicine Evolution of Reactive mPEG Polymers for the Conjugation of Peptides and Proteins
Current Organic Chemistry Natural Steroids and Androgen Antagonists used as Neuroprotection in Common Neurological Disorders
CNS & Neurological Disorders - Drug Targets Tuning hERG Out: Antitarget QSAR Models for Drug Development
Current Topics in Medicinal Chemistry P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Recent Trends of Chalcones Potentialities as Antiproliferative and Antiresistance Agents
Anti-Cancer Agents in Medicinal Chemistry Snake Venom Induced Local Toxicities: Plant Secondary Metabolites as an Auxiliary Therapy
Mini-Reviews in Medicinal Chemistry Syntheses and Preliminary Evaluation of Dual Target PET Probe [<sup>18</sup>F]-NOTA-Gly3- E (2PEG4-RGD-WH701) for PET Imaging of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in PET Imaging for Skeletal Surgery Applications
Recent Patents on Medical Imaging Development of New H1 Antihistamines: The Importance of Pharmacokinetics in the Evaluation of Safe and Therapeutically Effective Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Gemcitabine: A Critical Nucleoside for Cancer Therapy
Current Medicinal Chemistry Extracellular Signals for Guiding Mesenchymal Stem Cells Osteogenic Fate
Current Stem Cell Research & Therapy